Copenhagen, Denmark – April 20, 2025 – Minerva Imaging, an integrated CRO and CDMO specialized in targeted radionuclide therapies, today announced the acquisition of the Alpha-SPECTTM Mini system from MH3D, expanding its capabilities to support the rapidly growing actinium and alpha radiopharmaceutical therapy market. 

MH3D’s Alpha-SPECTTM Mini is a high-performance preclinical SPECT system specifically designed for highly sensitive imaging of alpha-emitting radiopharmaceuticals. Its advanced CZT-based detector technology enables precise detection, separation, and quantification of both parent radionuclides and their daughter isotopes, providing a powerful platform for the development and characterization of next-generation alpha therapies. 

“With the increasing clinical and commercial focus on actinium-based and other alpha-emitting therapies, there is a clear need for highly accurate and sensitive imaging solutions,” said Carsten H. Nielsen, CEO & Co-founder of Minerva Imaging. “The Alpha-SPECTTM Mini substantially enhances our ability to support our clients, particularly where in vivo biodistribution data and assessment of daughter isotopes are critical. We are excited to bring the first preclinical system in Europe, truly optimized for alpha-emitter theranostics, into our platform.” 

The addition of the Alpha-SPECTTM Mini further extends Minerva Imaging’s comprehensive preclinical imaging portfolio and underscores its commitment to staying at the forefront of advanced radiopharmaceutical imaging. By integrating alpha-optimized SPECT capabilities into its existing infrastructure, Minerva Imaging can offer more robust, quantitative insight to pharmaceutical and biotechnology partners developing alpha-emitting radiopharmaceuticals from early discovery through advanced preclinical stages. 

“We continuously listen to our customers and adapt our capabilities to meet their evolving needs,” added Carsten H. Nielsen. “This investment responds directly to growing demand for best-in-class imaging solutions for alpha therapies and further strengthens our position as a trusted partner in radiopharmaceutical development.” 

MH3D welcomed the deployment of the Alpha-SPECTTM Mini within Minerva Imaging’s workflow. “We are pleased to see the Alpha-SPECTTM Mini adopted by Minerva Imaging, an organization with deep expertise in radiopharmaceutical imaging,” said Xiaopei Huang, CEO and Founder of MH3D. “Their focus on alpha emitters and actinium-based therapies aligns closely with the system’s design principles of accuracy, sensitivity, and robust isotope characterization. As this will be the first system installed in Europe, we look forward to supporting Minerva Imaging in serving their partners and advancing the field of preclinical imaging globally.” 

With this acquisition, Minerva Imaging further strengthens its role as a leading partner to companies developing alpha-emitting radiopharmaceuticals, providing integrated discovery, in vivo imaging, and translational support to accelerate alpha therapy development. 

About MH3D, Inc. 

MH3D, Inc. is a medical imaging company developing next generation quantitative SPECT systems, powered by CZT detectors and advanced nuclear medicine imaging software. The company focuses on the Alpha-SPECTTM platform enabling absolute quantification for theranostics across pre-clinical and future clinical applications. Click here to learn more: https://www.mh3dinc.com

About Minerva Imaging 

Minerva Imaging is a fully integrated CRO and CDMO specialized in targeted radionuclide therapies. The company focusses on the use of advanced models within oncology, cardiovascular diseases and in vivo molecular imaging for translational research and drug development. Minerva Imaging engages with its clients to understand their scientific questions and discuss how its methods and capabilities can provide answers. The facility located in Denmark offers best–in–industry fully integrated radiopharmaceutical research, drug development and manufacturing services. Minerva’s competences are built on over 25 years of research within oncology and molecular imaging performed at the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark. Follow Minerva Imaging on LinkedIn for the latest news updates or visit www.minervaimaging.com for more information.